In Episode 2 of Dialogues on Digital Pathology, we speak to Dr. David Kleiner, Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, from the Center for Cancer Research at the National Cancer Institute.
Episode 2 with Dr. David Kleiner feat. Dr. Dean Tai - Dialogues on AI Digital Pathology.mp3
Introduction of Dr. David Kleiner
Dr. David Kleiner, M.D., Ph.D.
Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology,
Center for Cancer Research, National Cancer Institute.
A renowned liver pathologist, Dr. Kleiner is currently involved in multicentre clinical networks focusing on Non-alcoholic Fatty Liver Disease (also known as NAFLD) and has pursued research interests in automated quantification techniques for the assessment of NAFLD and NASH features in liver biopsies.
▲ A picture of David E. Kleiner, M.D., Ph.D.
Dr. Kleiner is responsible for overseeing the clinical service component of the Laboratory of Pathology. The laboratory serves as the anatomic pathology service for the NIH Clinical Center, supplying surgical pathology, hepatopathology, autopsy, cytopathology, flow cytometry, ultrastructural pathology, and cytogenetic diagnostic services. These services include both routine diagnostic services and pathology support for the many clinical research protocols carried out at the NIH.
Introduction of Dr. Dean Tai
Dr Dean Tai
Co-founder & Chief Scientific Officer (CSO) of HistoIndex
As the CSO of HistoIndex, Dr. Dean Tai is responsible for the strategic product development and research collaboration with clinical key opinion leaders globally.
Together with his HistoIndex co-founder, Dr. Gideon Ho, Dean completed prototyping and manufacturing of products for HistoIndex in Singapore and Europe and successfully implemented the products in Singapore, China, Taiwan, and USA. He also established multi-centre clinical trials for the company’s inventions with global clinical key opinion leaders, and successfully coordinated pre-clinical and started clinical validation in Singapore.
▲ A picture of Dr. Dean Tai
Furthermore, Dean established the world’s first stain-free imaging database for fibrosis diseases study in chronic liver and kidney diseases, and implemented it in several countries across Asia and Europe. With his guidance, HistoIndex won the BioSpectrum Asia Pacific Bioscience Industry Emerging Company of the Year Award in 2012.
关于我们
新加坡医疗科技公司HistoIndex，是杭州筹图科技有限公司的母公司，我们利用人工智能的图像分析技术和全球独创的无染色成像技术相结合应用于疾病进展的评价，特别是NASH新药开发的病理评价中。目前该技术平台已经在NASH临床前的多个动物模型和多个II，III期临床试验上做了深入研究和算法验证，已经参与完成近四十家国际国内知名药企、大型CRO公司和科研机构主办的相关试验。
